Paper Details

  1. Home
  2. Paper Details

Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.

Author: , AgarwalRajiv, ArnoldSusan, BakoGabriel, BlockGeoffrey A, BurkeSteven, CastilloFausto P, ChertowGlenn M, EckardtKai-Uwe, FaragYoussef M K, JardineAlan G, KhawajaZeeshan, KouryMark J, LewisEldrin F, LinTim, LuoWenli, MaroniBradley J, MatsushitaKunihiro, McCulloughPeter A, ParfreyPatrick S, PergolaPablo E, Roy-ChaudhuryPrabir, SarnakMark J, SharmaAmit, SpinowitzBruce, TsengCarol, TumlinJames, VargoDennis L, WaltersKimberly A, WinkelmayerWolfgang C, WittesJanet

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

Vadadustat was compared to darbepoetin alfa in two phase 3 trials for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vadadustat was noninferior to darbepoetin alfa for hematologic efficacy but did not meet the prespecified noninferiority criterion for cardiovascular safety.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production. METHODS: In two phase 3, randomized, open-label, active-controlled, noninferiority trials, we compared vadadustat ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2035938

データ提供：米国国立医学図書館（NLM）

Vadadustat: A New Oasis in Anemia Management for CKD Patients

The arid landscape of chronic kidney disease (CKD) presents numerous challenges, including anemia. This study explores the potential of vadadustat, a novel oral medication, to address anemia in patients with non-dialysis-dependent CKD. The researchers compared vadadustat to a traditional erythropoiesis-stimulating agent (ESA) in a large clinical trial. The study found that vadadustat was non-inferior to darbepoetin alfa in terms of improving hemoglobin levels but did not meet the non-inferiority criterion for cardiovascular safety.

Vadadustat: A Promising Treatment for CKD Anemia

This study suggests that vadadustat may be a viable treatment option for patients with CKD-related anemia. While vadadustat did not demonstrate non-inferiority for cardiovascular safety, its effectiveness in improving hemoglobin levels is noteworthy. This finding may lead to new strategies for managing anemia in CKD patients.

Navigating the Desert of CKD Treatment

This research provides valuable insights into the evolving landscape of CKD management. The study highlights the need for continued research to evaluate the long-term safety and efficacy of vadadustat in patients with CKD.

Dr. Camel's Conclusion

Vadadustat offers a potential oasis for patients struggling with CKD-related anemia. While further research is needed to fully understand its cardiovascular safety profile, its ability to improve hemoglobin levels makes it a promising treatment option. As we continue to explore the vast desert of CKD research, we may find new and innovative solutions that enhance the lives of patients facing this challenging condition.

Date :
  1. Date Completed 2021-05-05
  2. Date Revised 2021-10-14
Further Info :

Pubmed ID

33913637

DOI: Digital Object Identifier

10.1056/NEJMoa2035938

Related Literature

Article Analysis
・Effects of vadadustat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.